Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a diversified, specialty pharmaceutical company, announced the pricing of its offering of US$210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The offering was upsized from the previously announced offering size of US$175,000,000 aggregate principal amount of notes. Collegium also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional US$31,500,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on February 10, 2023, subject to customary closing conditions.
Latham & Watkins LLP is representing the initial purchasers in the offering with a corporate team led by New York/Los Angeles partner Greg Rodgers and Los Angeles partner Arash Aminian Baghai, with associates Samuel Niles, Ryan Gold, and James Dorian. Advice was also provided on tax matters by New York partner Elena Romanova, with associate Claire Park.